Aggregate sentiment
| Number of posts | Per cent | Ratio P/N | |
| bDMARD | |||
| Enbrel positive | 5210 | 18.4 | 1.35 |
| Enbrel negative | 3852 | 13.6 | |
| Infliximab positive | 2636 | 9.3 | 1.1 |
| Infliximab negative | 2405 | 8.5 | |
| Adalimumab positive | 4419 | 15.6 | 1.08 |
| Adalimumab negative | 4107 | 14.5 | |
| Certolizumab positive | 461 | 1.6 | 1.11 |
| Certolizumab negative | 415 | 1.5 | |
| Golimumab positive | 306 | 1.1 | 1.26 |
| Golimumab negative | 243 | 0.9 | |
| Tocilizumab positive | 384 | 1.4 | 1.40 |
| Tocilizumab negative | 274 | 1.0 | |
| Abatacept positive | 774 | 2.7 | 1.16 |
| Abatacept negative | 694 | 2.5 | |
| Tofacitinib positive | 346 | 1.2 | 1.71 |
| Tofacitinib negative | 202 | 0.7 | |
| Rituximab positive | 918 | 3.2 | 1.49 |
| Rituximab negative | 615 | 2.2 | |
| csDMARD | |||
| MTX positive | 9058 | 33.7 | 0.995 |
| MTX negative | 9103 | 33.9 | |
| HCQ positive | 3026 | 11.3 | 1.26 |
| HCQ negative | 2398 | 8.9 | |
| SZS positive | 803 | 3.0 | 0.97 |
| SZS negative | 827 | 3.1 | |
| LEF positive | 849 | 3.2 | 1.09 |
| LEF negative | 777 | 2.9 |
bDMARD, biological disease modifying anti-rheumatic drug; csDMARD, conventional synthetic disease modifying anti-rheumatic drug; HCQ, Hydroxychloroquine; LEF, Leflunomide; MTX, Methotrexate; SZS, Sulfasalazine.